Home > Quotes > ENZN

EnzonPharmaceuticals, Inc. Common Stock Quote & Summary Data

Get ENZN Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading ENZN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

EnzonPharmaceuticals, Inc. Common Stock Intraday Chart

News for ENZN

Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 0.51 $ 1.82
Low $ 0.50 $ 0.39

The current last sale of $0.5099 is 30.74% Higher thanthe 52 week low.

P/E Ratio

Company Description (as filed with the SEC)

Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the "Company," "we" or "us") receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®. We also had previously received royalty revenues from licensing arrangement related to sales of Oncaspar and Adagen until our rights to receive royalties on sales of these products expired in 2014. In addition, our rights to receive royalties on sales of Macugen and CIMZIA expired in the U.S. and Great Britain in 2014. The primary source of our royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. ("Merck"). We currently have no clinical operations and limited corporate operations. We have no intention of resuming any clinical development activities or acquiring new sources of royalty revenues.  ... More ...  

Nasdaq Official Price

Research Brokers before you trade

Want to trade FX?